Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899149 | 0.85 | TSHR (0.48) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 | |
| SCHEMBL30380635 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP19A1TSHRGPR35TDP1 | |
| SCHEMBL3016976 | 0.80 | VCAM1 (0.48) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 | |
| SCHEMBL18839539 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP19A1TSHRGPR35TDP1 | |
| SCHEMBL25371328 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 | |
| SCHEMBL18839527 | 0.75 | KMT2A (0.51) | ALDH1A1TSHRGPR35LMNAHTT | |
| SCHEMBL24150568 | 0.75 | ALDH1A1 (0.41) | ALDH1A1GPR35TDP1LMNAHTT | |
| SCHEMBL2796279 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 | |
| SCHEMBL212845 | 0.74 | CYP19A1 (0.81) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 | |
| SCHEMBL1943699 | 0.74 | CYP19A1 (0.62) | ALDH1A1CYP19A1HSD17B10TSHRGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527900-A | High-performance composite waterproof material and preparation method thereof | 深圳润符新材料科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-9132115-B2 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods | KAY HEIDI (US) | 2015-09-15 | — | — | US | claimed |
| US-20130253050-A1 | LIPID RAFT, CAVEOLIN PROTEIN,, AND CAVEOLAR FUNCTION MODULATION COMPOUNDS AND ASSOCIATED SYNTHETIC AND THERAPEUTIC METHODS | KAY HEIDI (US) | 2013-09-26 | — | — | US | claimed |
| US-8425921-B1 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods | KAY HEIDI (US) | 2013-04-23 | — | — | US | claimed |
| US-8026382-B2 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods | KAY HEIDI | 2011-09-27 | — | — | US | claimed |
| WO-2008144616-A1 | LIPID RAFT, CAVEOLIN PROTEIN, AND CAVEOLAR FUNCTION MODULATION COMPOUNDS AND ASSOCIATED SYNTHETIC AND THERAPEUTIC METHODS | KAY HEIDI (US) | 2008-11-27 | — | — | WO | claimed |
| US-20080286316-A1 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods | KAY HEIDI | 2008-11-20 | — | — | US | claimed |
| WO-2007006019-A1 | MATERIALS AND METHODS FOR SCREENING, DIAGNOSIS AND PROGNOSIS OF CONDITIONS ASSOCIATED WITH STAT PROTEIN EXPRESSION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-01-11 | — | — | WO | claimed |
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250277066-A1 | Substituted Pyridine-2,6-Bis(Phenylenephenolate) Complexes with Enhanced Solubility that are Useful as Catalyst Components for Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4608507-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | Neurocrine Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250250253-A1 | SALT FORMS AND POLYMORPHS OF (R)-1-(4-(6-(2-(4-(3,3-DIFLUOROCYCLOBUTOXY)-6-METHYLPYRIDIN-2-YL)ACETAMIDO) PYRIDAZIN-3-YL)-2-FLUOROBUTYL)-N-METHYL-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-07 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-4453972-A | Phenoxy pyridine derivatives and herbicidal compositions containing same | CELAMERCK GMBH & CO., KG (DE) | 1984-06-12 | — | — | US | disclosed |
| EP-0109640-A1 | Pyridine derivatives, their preparation and their application | CELAMERCK GmbH & Co. KG (DE) | 1984-05-30 | — | — | EP | disclosed |
| EP-0091596-A2 | Hydantoins, their preparation and application | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-10-19 | — | — | EP | disclosed |
| EP-0086375-A2 | Pyridine derivatives, their preparation and use | CELAMERCK GmbH & Co. KG (DE) | 1983-08-24 | — | — | EP | disclosed |
| EP-0053306-A1 | Pyridine derivatives, their preparation and uses | CELAMERCK GmbH & Co. KG (DE) | 1982-06-09 | — | — | EP | disclosed |
| US-3974166-A | FUNGICIDE | CIBA-GEIGY CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286316-A1 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods | CD4, VAPB, PXMP4 | ALDH1A1 4369/4885CYP19A1 4815/4885HSD17B10 3650/4885 |
| US-20250250253-A1 | SALT FORMS AND POLYMORPHS OF (R)-1-(4-(6-(2-(4-(3,3-DIFLUOROCYCLOBUTOXY)-6-METHYLPYRIDIN-2-YL)ACETAMIDO) PYRIDAZIN-3-YL)-2-FLUOROBUTYL)-N-METHYL-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE | GLS2, GLS, GLRA1 | ALDH1A1 875/4885CYP19A1 4005/4885HSD17B10 2806/4885 |
| US-20130253050-A1 | LIPID RAFT, CAVEOLIN PROTEIN,, AND CAVEOLAR FUNCTION MODULATION COMPOUNDS AND ASSOCIATED SYNTHETIC AND THERAPEUTIC METHODS | VAPB, CD4, VAPA | ALDH1A1 4236/4885CYP19A1 4824/4885HSD17B10 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.